New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
09:23 EDTSILC, VLO, LLY, ARIA, LUV, NFLX, LOGI, PCP, PSTI, AEO, LMT, UAL, CIE, ZHNE, INO, UNP, MCD, EBAYOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Netflix (NFLX), up 17%... Southwest Airlines (LUV), up 2.3%... Union Pacific (UNP), up 2%... Silicom (SILC), up 31%... Logitech (LOGI), up 16%... Lockheed Martin (LMT), up 1%... ALSO HIGHER: eBay (EBAY), up 2% after reporting earnings and guidance and also announcing it received a proposal from Carl Icahn regarding a spin-off of its PayPal unit... ARIAD (ARIA), up 10.6% after Daily Mail said Eli Lilly (LLY) approached the company about a possible deal... Inovio (INO), up 6.5% after announcing new immune activator... Pluristemae (PSTI), up 2.6% after receiving PEI approval for scaled-up 3D manufacturing... Valero (VLO), up 3% after giving Q4 guidance... Cobalt (CIE), up 4.6% after announcing first syn-rift discovery in deepwater Angola. DOWN AFTER EARNINGS: United Continental (UAL), up 2.9%... McDonald's (MCD), down 0.2%... Zhone (ZHNE), down 20%... Precision Castparts (PCP), down 2.5%. ALSO LOWER: American Eagle (AEO), down 6.4% after the company announced CEO Robert Hanson is leaving the company, to be replaced in interim by Jay Schottenstein.
News For NFLX;EBAY;UAL;LUV;MCD;LMT;ARIA;UNP;AEO;LLY;INO;PSTI;VLO;ZHNE;PCP;SILC;CIE;LOGI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
March 16, 2015
09:37 EDTNFLXActive equity options trading on open
Subscribe for More Information
08:14 EDTINOInovio, academic collaborators receives $16M HIV grant from NIAID
Subscribe for More Information
07:52 EDTNFLXNetflix downgraded at Evercore ISI
As previously reported, Evercore ISI downgraded Netflix to Sell from Hold. The firm downgraded shares and reduced its price target to $380 from $450 due to increasing competition among existing and emerging distributors combined with content providers who are becoming increasingly leveraged to new channels through OTT offerings of their own. Evercore ISI believes intensifying competition will necessitate increased investment with uncertain returns and lowered estimates.
07:27 EDTLLYBiodel BIOD-961 Phase 1 clinical trial meets primary efficacy endpoint
Biodel (BIOD) announced positive preliminary results from Study 6-101, a Phase 1 clinical trial comparing Biodel's lyophilized glucagon formulation BIOD-961, designed for use in a proprietary Glucagon Emergency Management, or GEM, auto-reconstitution device, to Eli Lilly's (LLY) Glucagon Emergency Rescue Kit and Novo Nordisk's GlucaGen HypoKit, which are marketed for the treatment of severe hypoglycemia. Study 6-101 was a randomized, single-center, double blind, six-period cross over study in 15 healthy volunteers who received each glucagon administered subcutaneously, or SC, and intramuscularly, or IM, in a randomized treatment sequence. The objectives of the study were to compare the pharmacokinetic, or PK, profiles, the pharmacodynamic, or PD, glucose, responses, and the PK/PD relationships of IM and SC dosing, as well as to assess safety profiles of the three test glucagons. Study 6-101 was a Phase 1 randomized, single-center, double blind, six-period cross over study designed to evaluate the PK and PD profiles of BIOD-961 compared to marketed glucagon formulations manufactured by Eli Lilly and Novo Nordisk. BIOD-961 is a lyophilized glucagon formulation designed for use in the GEM auto-reconstitution device. On six separate dosing days, each subject received 1 mg of one of the test glucagons delivered either SC or IM. Fifteen normal, healthy subjects were randomized into the study and ten completed all dosings. The objectives of the study were to compare the PK profiles, the PD responses, and the PK/PD relationships of IM and SC dosing, as well as to assess safety profiles of the three test glucagons. These data will facilitate selection of an appropriate marketed glucagon to use as a comparator in the planned pivotal study, in which the primary efficacy endpoint for approval is to demonstrate PK and PD bioequivalence of BIOD-961 to one of the marketed comparators.
06:50 EDTUNPUnion Pacific upgraded to Outperform from Neutral at Macquarie
Subscribe for More Information
06:35 EDTINOInovio reports Q4 EPS (12c), consensus (10c)
Subscribe for More Information
06:16 EDTNFLXNetflix downgraded to Sell from Hold at Evercore ISI
March 13, 2015
17:11 EDTNFLXSony Pictures TV nears streaming video deal for Seinfeld, WSJ reports
Subscribe for More Information
16:01 EDTNFLXOptions Update; March 13, 2015
Subscribe for More Information
13:27 EDTARIAARIAD drug granted orphan designation as GIST treatment
ARIAD Pharmaceuticals' Iclusig was granted FDA orphan status on February 12 as a treatment of gastrointestinal stromal tumors, or GIST, according to a post to the agency's site. Reference Link
10:00 EDTEBAYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:15 EDTEBAYeBay upgraded to Positive from Neutral at Susquehanna
Subscribe for More Information
March 12, 2015
16:01 EDTNFLX, MCDOptions Update; March 12, 2015
Subscribe for More Information
13:01 EDTLLYEli Lilly management to meet with SunTrust
Subscribe for More Information
10:01 EDTINOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:01 EDTLOGIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:36 EDTNFLXNielsen survey shows 36% Netflix household penetration
Subscribe for More Information
07:08 EDTINOInovio initiated with a Buy at H.C. Wainwright
Subscribe for More Information
06:39 EDTMCDMcDonald's move on antibiotics could pressure KFC,Reuters says
Subscribe for More Information
06:27 EDTLOGILogitech downgraded to Underweight from Neutral at JPMorgan
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use